- Report
- June 2025
- 73 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Report
- May 2025
- 198 Pages
Global
From €3183EUR$3,545USD£2,711GBP
€3537EUR$3,939USD£3,012GBP
- Report
- August 2023
- 180 Pages
Global
From €5342EUR$5,950USD£4,549GBP
- Report
- August 2023
- 98 Pages
Europe
From €5342EUR$5,950USD£4,549GBP
- Report
- October 2023
- 110 Pages
Global
From €4040EUR$4,500USD£3,441GBP
- Report
- February 2024
- 185 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP
- Report
- November 2023
- 175 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP
- Report
- October 2023
- 130 Pages
Europe
From €3053EUR$3,400USD£2,600GBP
€3591EUR$4,000USD£3,058GBP
The Recombinant Proteins Manufacturing market is a subset of the biopharmaceuticals industry, which focuses on the production of proteins through recombinant DNA technology. This technology involves the insertion of a gene from one organism into another, allowing for the production of proteins that are not naturally found in the organism. These proteins can be used for a variety of medical applications, such as the treatment of diseases, the development of vaccines, and the production of diagnostic tests. The Recombinant Proteins Manufacturing market is highly competitive, with a number of companies offering a range of products and services. Companies in this market include Lonza, Merck KGaA, Novozymes, and Thermo Fisher Scientific. Show Less Read more